US3507866A
(en)
|
1967-08-08 |
1970-04-21 |
Merck & Co Inc |
1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
|
US3567725A
(en)
|
1968-11-20 |
1971-03-02 |
Merck & Co Inc |
Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
|
US4294836A
(en)
|
1980-03-24 |
1981-10-13 |
Sterling Drug Inc. |
1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
|
US4294837A
(en)
|
1980-03-28 |
1981-10-13 |
Sterling Drug Inc. |
1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
|
US4317909A
(en)
|
1980-03-24 |
1982-03-02 |
Sterling Drug Inc. |
Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
|
US4309537A
(en)
|
1980-03-28 |
1982-01-05 |
Sterling Drug Inc. |
Production of imidazo[4,5-b]pyridin-2-ones or thiones
|
GB8709448D0
(en)
|
1987-04-21 |
1987-05-28 |
Pfizer Ltd |
Heterobicyclic quinoline derivatives
|
JPS63275582A
(ja)
|
1987-05-02 |
1988-11-14 |
Naade Kenkyusho:Kk |
2−アミノイミダゾ〔4,5−b〕ピリジン誘導体の製造方法
|
DD262026A1
(de)
|
1987-07-10 |
1988-11-16 |
Akad Wissenschaften Ddr |
Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
|
FR2643903A1
(fr)
|
1989-03-03 |
1990-09-07 |
Union Pharma Scient Appl |
Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
|
US4963561A
(en)
|
1990-02-28 |
1990-10-16 |
Sterling Drug Inc. |
Imidazopyridines, their preparation and use
|
TW274550B
(es)
|
1992-09-26 |
1996-04-21 |
Hoechst Ag |
|
DE19601627A1
(de)
|
1996-01-18 |
1997-07-24 |
Bayer Ag |
Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
|
US6031105A
(en)
|
1996-04-09 |
2000-02-29 |
Pfizer Inc |
Substituted pyridines
|
AU748849B2
(en)
|
1997-09-26 |
2002-06-13 |
Zentaris Gmbh |
Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
|
AU750564B2
(en)
|
1997-11-27 |
2002-07-25 |
Chugai Seiyaku Kabushiki Kaisha |
Examination method, examination reagent and remedy for diseases caused by variation in LKB1 gene
|
ZA9810490B
(en)
|
1997-12-03 |
1999-05-20 |
Dainippon Pharmaceutical Co |
2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
|
JP2003146987A
(ja)
|
1999-05-31 |
2003-05-21 |
Dainippon Pharmaceut Co Ltd |
2−アリールプリン−9−アセトアミド誘導体
|
WO2000072670A1
(fr)
|
1999-05-31 |
2000-12-07 |
Chugai Research Institute For Molecular Medicine, Inc. |
Animaux rompant le gene lkb1
|
JP3814125B2
(ja)
|
1999-06-02 |
2006-08-23 |
大日本住友製薬株式会社 |
2−アリール−8−オキソジヒドロプリン誘導体からなる医薬
|
JP2002100363A
(ja)
|
2000-09-25 |
2002-04-05 |
Mitsubishi Chemicals Corp |
リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
|
JP2002167387A
(ja)
|
2000-11-29 |
2002-06-11 |
Dainippon Pharmaceut Co Ltd |
2−(7,8−ジヒドロ−8−オキソ−9h−プリン−9−イル)酢酸誘導体
|
AU2002220276A1
(en)
|
2000-12-12 |
2002-06-24 |
Neurogen Corporation |
Spiro(isobenzofuran-1,4'-piperidin)-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
|
WO2002076954A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
KR100955589B1
(ko)
|
2001-09-04 |
2010-04-30 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
신규한 디하이드로프테리디논, 이의 제조방법 및 이를 함유하는 약제학적 조성물
|
US6825184B2
(en)
|
2001-10-18 |
2004-11-30 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-Disubstituted benzo-fused urea compounds
|
CN100522999C
(zh)
|
2002-02-14 |
2009-08-05 |
免疫医疗公司 |
抗cd20抗体及其融合蛋白和使用方法
|
TWI314928B
(en)
|
2002-02-28 |
2009-09-21 |
Novartis A |
5-phenylthiazole derivatives and use as pi3 kinase inhibitors
|
US7247621B2
(en)
|
2002-04-30 |
2007-07-24 |
Valeant Research & Development |
Antiviral phosphonate compounds and methods therefor
|
MXPA04010983A
(es)
|
2002-05-06 |
2005-02-14 |
Genelabs Tech Inc |
Derivados de nucleosidos para tratar infecciones por el virus de la hepatitis c.
|
AU2003299531A1
(en)
|
2002-08-05 |
2004-06-07 |
University Of Massachusetts |
Compounds for modulating rna interference
|
US7199119B2
(en)
|
2002-10-31 |
2007-04-03 |
Amgen Inc. |
Antiinflammation agents
|
AU2003295776B2
(en)
|
2002-11-21 |
2011-05-12 |
Novartis Vaccines And Diagnostics, Inc. |
2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
|
BRPI0406809A
(pt)
|
2003-01-17 |
2005-12-27 |
Warner Lambert Co |
Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
|
KR100983462B1
(ko)
|
2003-02-26 |
2010-09-27 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
디하이드로프테리디논, 이의 제조방법 및 약제로서의 이의 용도
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
GB0305152D0
(en)
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
GB2400101A
(en)
|
2003-03-28 |
2004-10-06 |
Biofocus Discovery Ltd |
Compounds capable of binding to the active site of protein kinases
|
TW200519106A
(en)
|
2003-05-02 |
2005-06-16 |
Novartis Ag |
Organic compounds
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
SI2604620T1
(sl)
|
2003-05-30 |
2016-10-28 |
Gilead Pharmasset LLC c/o Gilead Sciences, Inc. |
Modificirani fluorirani nukleozidni analogi
|
WO2005013894A2
(en)
|
2003-06-26 |
2005-02-17 |
Merck & Co., Inc. |
Benzodiazepine cgrp receptor antagonists
|
JP2007530000A
(ja)
|
2003-07-17 |
2007-11-01 |
ユニヴァーシティー オブ ダンディー |
Lkb1/strad7m025複合体の使用方法
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
GB0320197D0
(en)
|
2003-08-28 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
US20080194019A1
(en)
|
2003-09-09 |
2008-08-14 |
Beth Israel Deaconess Medical Center, Inc. |
Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
|
CA2569406A1
(en)
|
2004-06-04 |
2005-12-22 |
Icos Corporation |
Methods for treating mast cell disorders
|
DE102004029784A1
(de)
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
WO2006001266A1
(ja)
|
2004-06-23 |
2006-01-05 |
Banyu Pharmaceutical Co., Ltd. |
2-アリールプリン誘導体の製造方法
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
AU2005289644A1
(en)
|
2004-09-24 |
2006-04-06 |
Janssen Pharmaceutica, N.V. |
Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
|
GB0423653D0
(en)
|
2004-10-25 |
2004-11-24 |
Piramed Ltd |
Pharmaceutical compounds
|
US8153640B2
(en)
|
2004-10-29 |
2012-04-10 |
Tibotec Pharmaceuticals Ltd. |
HIV inhibiting bicyclic pyrimdine derivatives
|
US7855205B2
(en)
|
2004-10-29 |
2010-12-21 |
Janssen Pharmaceutica Nv |
Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
|
SE0403006D0
(sv)
|
2004-12-09 |
2004-12-09 |
Biovitrum Ab |
New compounds
|
CA2590294A1
(en)
|
2004-12-13 |
2006-06-22 |
Sunesis Pharmaceuticals, Inc. |
Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
|
RU2405780C2
(ru)
|
2005-02-16 |
2010-12-10 |
Астразенека Аб |
Химические соединения
|
WO2006091737A1
(en)
|
2005-02-24 |
2006-08-31 |
Kemia, Inc. |
Modulators of gsk-3 activity
|
MX2007010401A
(es)
|
2005-02-25 |
2008-02-19 |
Kudos Pharm Ltd |
Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor.
|
CA2599320A1
(en)
|
2005-02-25 |
2006-08-31 |
Kudos Pharmaceuticals Limited |
Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
|
JP4813465B2
(ja)
|
2005-03-31 |
2011-11-09 |
バイオメディクス株式会社 |
抗cd20モノクローナル抗体
|
NZ562468A
(en)
|
2005-04-05 |
2009-10-30 |
Pharmacopeia Inc |
Purine and imidazopyridine derivatives for immunosuppression
|
KR20080031001A
(ko)
|
2005-06-02 |
2008-04-07 |
아스트라제네카 아베 |
Cd20에 대한 항체 및 그의 용도
|
NZ566903A
(en)
|
2005-10-07 |
2011-09-30 |
Exelixis Inc |
Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors
|
KR20140033237A
(ko)
|
2005-10-07 |
2014-03-17 |
엑셀리시스, 인코포레이티드 |
포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법
|
WO2007044698A1
(en)
|
2005-10-07 |
2007-04-19 |
Exelixis, Inc. |
PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
|
US8628931B2
(en)
|
2005-10-18 |
2014-01-14 |
George Mason Intellectual Properties, Inc. |
mTOR pathway theranostic
|
PT1951724E
(pt)
|
2005-11-17 |
2011-08-02 |
Osi Pharm Inc |
Inibidores mtor fundidos bicíclicos
|
PL1954699T3
(pl)
|
2005-11-22 |
2013-01-31 |
Kudos Pharm Ltd |
Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR
|
GB0525083D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
GB0525080D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
CA2635997A1
(en)
|
2006-01-11 |
2007-07-19 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives and their use in therapy
|
US20090281075A1
(en)
|
2006-02-17 |
2009-11-12 |
Pharmacopeia, Inc. |
Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
|
EP2043655A2
(en)
|
2006-04-25 |
2009-04-08 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
NZ572812A
(en)
|
2006-04-26 |
2010-09-30 |
Hoffmann La Roche |
THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
|
EP2016068A1
(en)
|
2006-05-03 |
2009-01-21 |
AstraZeneca AB |
Pyrazole derivatives and their use as pi3k inhibitors
|
US20090076009A1
(en)
|
2006-05-03 |
2009-03-19 |
Arnould Jean-Claude Retired |
Thiazole derivatives and their use as anti-tumour agents
|
WO2007135398A1
(en)
|
2006-05-22 |
2007-11-29 |
Astrazeneca Ab |
Indole derivatives
|
KR101410453B1
(ko)
|
2006-08-02 |
2014-06-27 |
싸이토키네틱스, 인코포레이티드 |
소정의 화학 물질, 조성물 및 방법
|
LT2057156T
(lt)
|
2006-08-23 |
2017-05-25 |
Kudos Pharmaceuticals Limited |
2-metilmorfolino pirido-, pirazo- ir pirimidopirimidino dariniai kaip mtor slopikliai
|
US20100144738A1
(en)
|
2006-09-05 |
2010-06-10 |
William Bornmann |
Inhibitors of c-met and uses thereof
|
EP2063882A4
(en)
|
2006-09-05 |
2010-03-03 |
Univ Emory |
TYROSINKINASE INHIBITOR FOR PREVENTING OR TREATING INFECTIONS
|
WO2008032077A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
WO2008032060A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032033A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
EP2064203A1
(en)
|
2006-09-14 |
2009-06-03 |
AstraZeneca AB |
2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032028A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
CN101595103A
(zh)
|
2006-09-14 |
2009-12-02 |
阿斯利康(瑞典)有限公司 |
嘧啶衍生物
|
WO2008032036A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032027A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
WO2008032089A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032091A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
DK2420498T3
(en)
|
2006-09-26 |
2017-08-14 |
Celgene Corp |
5-substituted quinazolinone derivatives as anticancer agents
|
AR063142A1
(es)
|
2006-10-04 |
2008-12-30 |
Pharmacopeia Inc |
Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
|
US7902187B2
(en)
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
RU2478635C2
(ru)
|
2006-10-19 |
2013-04-10 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
|
CN101679432B
(zh)
|
2006-10-19 |
2015-04-22 |
西格诺药品有限公司 |
杂芳基化合物、其组合物及其作为蛋白激酶抑制剂的用途
|
EP2364981A1
(en)
|
2006-11-20 |
2011-09-14 |
Novartis AG |
Salts and crystalline forms of 2-methyl-2-[4- (3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
|
US20080234262A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
UA99284C2
(ru)
|
2007-05-11 |
2012-08-10 |
Елі Ліллі Енд Компані |
ИНГИБИТОРЫ р70 S6-КИНАЗЫ
|
WO2009007751A2
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
BRPI0814818A2
(pt)
|
2007-07-09 |
2019-09-10 |
Astrazeneca Ab |
composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica
|
WO2009007750A1
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
|
EP2178916B1
(en)
|
2007-07-31 |
2014-12-17 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to human cd20 and method of using thereof
|
WO2009030368A1
(en)
|
2007-09-05 |
2009-03-12 |
F. Hoffmann-La Roche Ag |
Combination therapy with type i and type ii anti-cd20 antibodies
|
NZ584425A
(en)
|
2007-09-26 |
2012-03-30 |
Celgene Corp |
6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
|
AU2008312631A1
(en)
|
2007-10-16 |
2009-04-23 |
Wyeth Llc |
Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
|
AU2008345225A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
AU2009205501A1
(en)
|
2008-01-15 |
2009-07-23 |
Wyeth Llc |
3H-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their syntheses
|
US20110091574A1
(en)
|
2008-02-15 |
2011-04-21 |
Catholic Healthcare West |
Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox2 inhibitor
|
KR101892989B1
(ko)
|
2008-06-27 |
2018-08-30 |
셀젠 카르 엘엘씨 |
헤테로아릴 화합물 및 이의 용도
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
US8110578B2
(en)
*
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
KR20160091440A
(ko)
*
|
2008-11-13 |
2016-08-02 |
길리아드 칼리스토가 엘엘씨 |
혈액 종양에 대한 요법
|
EP2379561B1
(en)
|
2008-11-25 |
2015-11-04 |
University Of Rochester |
Mlk inhibitors and methods of use
|
CN102448472A
(zh)
|
2009-05-25 |
2012-05-09 |
国立大学法人东京工业大学 |
包含与中枢神经细胞的增殖和分化相关的核因子的药物组合物
|
WO2011031965A1
(en)
|
2009-09-14 |
2011-03-17 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
EP2493472B1
(en)
*
|
2009-10-26 |
2016-12-07 |
Signal Pharmaceuticals, LLC |
Methods of synthesis and purification of heteroaryl compounds
|
CN102762568A
(zh)
|
2009-12-23 |
2012-10-31 |
伊兰药品公司 |
作为polo样激酶的抑制剂的蝶啶酮
|
EP2992878A1
(en)
|
2010-02-03 |
2016-03-09 |
Signal Pharmaceuticals, LLC |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
CA2792872A1
(en)
|
2010-03-12 |
2011-09-15 |
Celgene Corporation |
Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
|
US20110318336A1
(en)
|
2010-03-29 |
2011-12-29 |
George Mason Intellectual Properties, Inc. |
Identification and Treatment of Aggressive Lung Cancer Tumors
|
US20120028972A1
(en)
*
|
2010-07-30 |
2012-02-02 |
Lilly Wong |
Biomarker assays for detecting or measuring inhibition of tor kinase activity
|
RU2013145556A
(ru)
*
|
2011-03-11 |
2015-04-20 |
Селджин Корпорейшн |
Применение 3-(5-амино-2-метил-4-оксохиназолин-3(4н)-ил)пиперидин-2,6-диона в лечении иммунных и воспалительных заболеваний
|
CN105039520A
(zh)
|
2011-08-03 |
2015-11-11 |
西格诺药品有限公司 |
作为lkb1状态的预测性生物标志物的基因表达谱的鉴定
|
CN107157990B
(zh)
*
|
2011-10-19 |
2020-01-07 |
西格诺药品有限公司 |
利用tor激酶抑制剂治疗癌症
|
UA114496C2
(uk)
*
|
2011-12-02 |
2017-06-26 |
Сігнал Фармасьютікалз, Елелсі |
ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ 7-(6-(2-ГІДРОКСИПРОПАН-2-ІЛ)ПІРИДИН-3-ІЛ)-1-((ТРАНС)-4-МЕТОКСИЦИКЛОГЕКСИЛ)-3,4-ДИГІДРОПІРАЗИНО[2,3-b]ПІРАЗИН-2(1H)-ОНУ, ЇХ ТВЕРДІ ФОРМИ І СПОСОБИ ЇХ ЗАСТОСУВАННЯ
|
EA028462B1
(ru)
|
2012-02-24 |
2017-11-30 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Способы лечения немелкоклеточного рака легких на поздних стадиях c применением комбинированного лечения с ингибитором киназы tor
|
KR102057357B1
(ko)
|
2012-03-15 |
2019-12-18 |
시그날 파마소티칼 엘엘씨 |
Tor 키나제 억제제를 사용한 암의 치료
|
EP2825169B1
(en)
|
2012-03-15 |
2018-05-09 |
Signal Pharmaceuticals, LLC |
Treatment of cancer with tor kinase inhibitors
|
EA028434B1
(ru)
|
2012-03-15 |
2017-11-30 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Лечение рака ингибиторами tor киназы
|
KR20210071101A
(ko)
|
2012-03-15 |
2021-06-15 |
시그날 파마소티칼 엘엘씨 |
Tor 키나제 억제자를 사용하는 암의 치료
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
WO2014172426A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
CA2908353C
(en)
|
2013-04-17 |
2021-11-02 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
TW201527300A
(zh)
|
2013-04-17 |
2015-07-16 |
Signal Pharm Llc |
關於1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氫吡并[2,3-b]吡-2(1H)-酮之醫藥調配物、方法、固態型式及使用方法
|
JP6382948B2
(ja)
|
2013-04-17 |
2018-08-29 |
シグナル ファーマシューティカルズ,エルエルシー |
癌を治療するためのtorキナーゼ阻害剤及びシチジン類似体を含む組合せ療法
|
US9937169B2
(en)
|
2013-04-17 |
2018-04-10 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
|
JP2016522177A
(ja)
|
2013-04-17 |
2016-07-28 |
シグナル ファーマシューティカルズ,エルエルシー |
ジヒドロピラジノ−ピラジンによる癌治療
|
US9358232B2
(en)
*
|
2013-04-17 |
2016-06-07 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
MX2015014596A
(es)
*
|
2013-04-17 |
2016-03-03 |
Signal Pharm Llc |
Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
|